Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 15/20 | 0.68 |
| ▸ | TNKS2 | Q9H2K2 | 15/20 | 0.68 |
| ▸ | PARP1 | P09874 | 14/20 | 0.68 |
| ▸ | PARP2 | Q9UGN5 | 4/20 | 0.63 |
| ▸ | GUSB | P08236 | 3/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17830142 | 0.98 | TNKS (0.70) | TNKSTNKS2PARP1PARP2GUSB | |
| SCHEMBL17829769 | 0.93 | TNKS (0.60) | TNKSTNKS2PARP1PARP2GUSB | |
| SCHEMBL11086311 | 0.87 | TNKS (0.74) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL17829728 | 0.84 | TNKS (0.57) | TNKSTNKS2PARP1PARP2GUSB | |
| SCHEMBL17829780 | 0.84 | TNKS (0.57) | TNKSTNKS2PARP1PARP2GUSB | |
| SCHEMBL17829779 | 0.84 | TNKS (0.57) | TNKSTNKS2PARP1PARP2GUSB | |
| SCHEMBL17829782 | 0.83 | TNKS (0.59) | TNKSTNKS2PARP1PARP2 | |
| SCHEMBL17829784 | 0.82 | PARP1 (0.55) | TNKSTNKS2PARP1PARP2GUSB | |
| SCHEMBL17829671 | 0.82 | GUSB (0.58) | TNKSTNKS2PARP1PARP2GUSB | |
| SCHEMBL15775476 | 0.81 | TNKS (1.00) | TNKSTNKS2PARP1PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | TNKS 1771/4885TNKS2 2811/4885PARP1 2477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.